ProfileGDS5678 / 1436241_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 54% 53% 56% 57% 56% 56% 62% 55% 55% 56% 53% 56% 55% 55% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3956854
GSM967853U87-EV human glioblastoma xenograft - Control 23.2931353
GSM967854U87-EV human glioblastoma xenograft - Control 33.4010556
GSM967855U87-EV human glioblastoma xenograft - Control 43.3925857
GSM967856U87-EV human glioblastoma xenograft - Control 53.3493156
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5132456
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.7757362
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3771455
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3729255
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3832156
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2987953
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3738256
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3895155
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3879955